CVS Caremark will cover Lilly’s weight loss drug Zepbound once again

CVS Caremark will restore coverage of Eli Lilly’s Zepbound by Oct. 1, and Lilly’s new weight-loss pill Foundayo will be added starting Monday. The change applies to CVS Caremark’s standard formulary, covering about 25 million to 30 million people, and could lower out-of-pocket costs for some patients to as little as a $25 copay. The move is positive for Lilly’s access and reimbursement prospects, though employer plan decisions still determine final coverage and a class-action lawsuit over last year’s removal remains active.

Analysis

This is more important for NVO than the headline suggests because formulary placement drives habit persistence, not just incremental starts. Once a payer reinstates broad access to a GLP-1, the default market share tends to migrate back toward the product with the strongest perceived efficacy, and Zepbound has been the best-in-class reference point in patient forums and prescriber behavior. That creates a slow-burn share reallocation over the next 1-2 quarters, especially among commercially insured patients where out-of-pocket friction is the main conversion hurdle.

The second-order effect is on the negotiating leverage of PBMs and employers, not just Lilly’s top line. CVS reversing course signals that exclusivity-based steering is losing power in this category, which likely compresses the ability of PBMs to extract rebates by threatening access cuts. Over time, that should narrow the gap between net and gross pricing across obesity drugs, but it also means manufacturers with superior products can defend share without relying on rebate wars.

For NVO, the risk is less about a sudden collapse and more about a gradual erosion of Wegovy's “default” position in covered lives. If Zepbound regains broad access while Mounjaro remains protected, the market may start to treat Novo’s obesity franchise as structurally second-tier unless it can re-accelerate on supply, convenience, or next-gen pipeline. The contrarian angle is that the market may be underestimating how sticky prior switchers can be once they have seen better efficacy on Lilly’s asset.

A key tail risk for the bullish Lilly view is employer-level carve-outs: if large plans keep excluding obesity coverage, the headline formulary win may not translate into the expected volume step-up. But that is a months-long implementation issue, not a thesis breaker, and it argues for a measured entry rather than chasing the move immediately after the announcement.

Key Decisions for Investors

• Short-term: avoid adding to NVO ahead of the next utilization data print; use any post-headline strength to trim exposure, as the next 1-2 quarters could show gradual share leakage to Lilly rather than an immediate collapse.
• Pair trade: long LLY / short NVO for a 2-4 month horizon, targeting relative outperformance if reinstated formulary access converts into higher refill persistence; stop if employer carve-outs materially limit Zepbound uptake.
• Buy NVO downside protection: 3-6 month put spreads financed against existing long exposure, since the main risk is incremental not catastrophic but could compress multiple if obesity growth decelerates.
• For tactical traders, wait for the first pullback after the announcement before initiating any LLY momentum long; the edge is in the subsequent claims data, not the headline, with a favorable 3-6 month risk/reward if access broadens as expected.